Amgen said dazodalibep, its CD40 ligand antagonist for Sjögren’s disease, met statistically significant and clinically meaningful goals in preliminary Phase 3 results. The company framed the outcome as positioning the asset to compete with established antibody approaches under an FDA review. The update is notable for Sjögren’s, where unmet need remains high and late-stage trial design increasingly relies on clinically interpretable endpoints. A positive Phase 3 readout also signals that Horizon’s acquired pipeline continues to deliver credible de-risking milestones for investors.